SLC5A2 and chronic kidney disease: For example, in the CREDENCE trial, the addition of a sodium-glucose cotransporter-2 inhibitor to routine therapy for patients with type 2 diabetes and CKD reduced per-participant annual GHG emissions from 196 kg CO2e to 157 kg CO2e by preventing hospital admissions and delaying dialysis.45